Loading
A phase 3 trial of Tarlatamab, Durvalumab, Carboplatin in small-cell lung cancer, run by Amgen, active and no longer recruiting.
A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC) is a phase 3 interventional study registered as NCT07005128 by Amgen, with 350 participants enrolled, started 2025-08-18 and due to reach its primary completion in 2029-01-04. Interventions recorded: Tarlatamab, Durvalumab, Carboplatin, Etoposide. Conditions listed: Small-cell Lung Cancer, Extensive Stage Small-cell Lung Cancer. No results are recorded here; the registry entry is the source.
Shares Tarlatamab, Amgen, Extensive-stage small-cell lung cancer, T-cell engagers (bispecific).
Shares Extensive-stage small-cell lung cancer, Etoposide, Topoisomerase-I inhibitors (and ADC payloads), Platinum agents.
Shares Extensive-stage small-cell lung cancer, Etoposide, Topoisomerase-I inhibitors (and ADC payloads), Platinum agents.
Shares Extensive-stage small-cell lung cancer, Etoposide, Topoisomerase-I inhibitors (and ADC payloads), Platinum agents.
Shares Extensive-stage small-cell lung cancer, Etoposide, Topoisomerase-I inhibitors (and ADC payloads), Platinum agents.
Shares Extensive-stage small-cell lung cancer, Etoposide, Durvalumab, Carboplatin.
Shares Extensive-stage small-cell lung cancer, Etoposide, Topoisomerase-I inhibitors (and ADC payloads), Carboplatin.
Shares Extensive-stage small-cell lung cancer, Etoposide, Topoisomerase-I inhibitors (and ADC payloads), Platinum agents.